Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However, the associa...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | inglés |
| Publicado: |
2017
|
| Acceso en línea: | https://doi.org/10.18632/oncotarget.21602 https://www.oncotarget.com/article/21602/pdf/ |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|